# GERD and Dyspepsia: Diagnosis Without Overreliance on PPIs

## Introduction

Gastroesophageal reflux disease (GERD) and dyspepsia are among the most common gastrointestinal complaints in primary care. While proton pump inhibitors (PPIs) are highly effective, their widespread and often indefinite use has raised concerns about long-term adverse effects and the medicalization of symptoms that may respond to lifestyle changes or alternative approaches.

## Definitions

GERD is a condition in which reflux of gastric contents causes troublesome symptoms such as heartburn and regurgitation, or complications including erosive esophagitis, stricture, and Barrett esophagus. Dyspepsia refers to epigastric pain or discomfort, early satiety, or postprandial fullness, which may be functional (without an identified structural cause) or secondary to an underlying condition such as peptic ulcer or gastric cancer. Functional dyspepsia is defined by Rome IV criteria as symptoms present for at least 3 months with onset at least 6 months prior, without structural explanation on upper endoscopy.

## Diagnosis of GERD

### Clinical Diagnosis

Typical symptoms of heartburn and acid regurgitation are sufficient for empiric diagnosis in patients without alarm features. Atypical symptoms such as chronic cough, laryngitis, chest pain, and asthma exacerbation are less reliably attributed to GERD. Symptom response to a 4- to 8-week PPI trial supports but does not confirm the diagnosis. Diagnosing GERD based solely on PPI response should be avoided, as the placebo response rate is approximately 20 to 40%.

### Alarm Features Requiring Endoscopy

Alarm features include dysphagia (difficulty swallowing), unintentional weight loss, GI bleeding or iron-deficiency anemia, persistent vomiting, age 60 or older with new-onset symptoms, and family history of upper GI malignancy.

| Alarm Feature | Concern | Action |
|---------------|---------|--------|
| Dysphagia | Stricture, malignancy | Upper endoscopy |
| Unintentional weight loss | Malignancy | Upper endoscopy |
| GI bleeding / iron-deficiency anemia | Ulcer, malignancy | Upper endoscopy |
| Persistent vomiting | Obstruction, malignancy | Upper endoscopy |
| Age ≥60 with new-onset symptoms | Malignancy | Upper endoscopy |
| Family history of upper GI malignancy | Increased cancer risk | Upper endoscopy |

### Diagnostic Testing

Upper endoscopy (EGD) evaluates for erosive esophagitis, Barrett esophagus, stricture, and malignancy. Ambulatory pH monitoring (wireless Bravo or catheter-based) is the gold standard for quantifying acid exposure and should be performed off PPI to confirm a GERD diagnosis. Esophageal manometry evaluates motility and is indicated before anti-reflux surgery. H. pylori testing using non-invasive methods (stool antigen or urea breath test) is recommended for dyspepsia, with treatment if positive.

![Diagnostic algorithm for GERD and dyspepsia in primary care showing when to pursue empiric therapy versus endoscopy](images/gerd-dyspepsia-algorithm.jpg)

## Approach to Dyspepsia

### Test-and-Treat Strategy for H. pylori

For patients under 60 without alarm features, testing for H. pylori should precede PPI initiation. The stool antigen test (preferred) or urea breath test provides non-invasive diagnosis. PPIs must be held for 2 weeks before H. pylori testing to avoid false negatives. Positive results are treated with quadruple therapy consisting of a PPI plus bismuth, metronidazole, and tetracycline for 14 days. Eradication is confirmed with a stool antigen or breath test at least 4 weeks after completing treatment.

### Functional Dyspepsia Management

If H. pylori is negative and no alarm features are present, a trial of PPI for 4 to 8 weeks is appropriate, followed by reassessment. For PPI-unresponsive symptoms, a tricyclic antidepressant such as amitriptyline at 10 to 25 mg nightly can serve as a neuromodulator. Prokinetics such as metoclopramide may help postprandial distress syndrome but should be used with caution due to the risk of tardive dyskinesia. Cognitive behavioral therapy and gut-directed hypnotherapy have emerging evidence for functional dyspepsia.

## Lifestyle Modifications for GERD

Weight loss is the single most effective lifestyle intervention, with even modest weight loss improving symptoms. Elevating the head of the bed by 6 to 8 inches (not just adding extra pillows) helps nocturnal symptoms. Eating should be avoided within 2 to 3 hours of bedtime. Personal dietary triggers should be identified and limited, with common triggers including coffee, alcohol, spicy foods, fatty foods, chocolate, and peppermint. Smoking cessation and avoiding tight-fitting clothing around the abdomen are additional measures.

## PPI Therapy: Appropriate Use

### When PPIs Are Indicated

PPIs are indicated for erosive esophagitis (initial healing course of 8 weeks), Barrett esophagus (long-term therapy recommended), severe GERD symptoms not responsive to lifestyle changes and H2 receptor antagonists, NSAID gastroprophylaxis in high-risk patients, and Zollinger-Ellison syndrome.

### PPI De-Prescribing

Many patients are on PPIs indefinitely without a clear indication. After 4 to 8 weeks of therapy, an attempt to step down or discontinue should be made. Step-down strategies include switching to an H2 receptor antagonist such as famotidine, reducing PPI use to on-demand dosing, or tapering to the lowest effective dose. Patients should be warned about rebound acid hypersecretion, a transient worsening of symptoms for 1 to 2 weeks after discontinuation that is self-limited. Patients with documented erosive esophagitis, Barrett esophagus, or prior complications may require long-term PPI therapy, which should be reassessed annually.

![Diagram showing a PPI step-down protocol from daily PPI to H2RA to on-demand therapy](images/ppi-stepdown-protocol.jpg)

## Long-Term PPI Concerns

Long-term PPI use has been associated with increased risk of Clostridioides difficile infection, particularly in hospitalized patients on antibiotics. A modest association with osteoporosis and fractures has been observed, though clinical significance is debated. Hypomagnesemia should be monitored, especially in patients also taking diuretics. Observational associations with chronic kidney disease exist, though causality has not been established. Reduced absorption of vitamin B12 and iron can occur with chronic acid suppression. A small increase in community-acquired pneumonia risk has been noted. These associations are largely from observational data, and absolute risk increases are small, but they warrant consideration when benefits are marginal.

## Alternative and Adjunctive Therapies

H2 receptor antagonists such as famotidine are effective for mild GERD and nocturnal symptoms. Alginate-based antacids (Gaviscon Advance) form a mechanical barrier on the gastric surface and are effective for postprandial reflux. Baclofen reduces transient lower esophageal sphincter relaxations but is limited by CNS side effects. Surgical fundoplication is an option for patients with documented GERD who desire to discontinue PPI therapy or have refractory symptoms despite maximal medical therapy.

![Comparison chart of medical therapy options for GERD showing efficacy profiles and side effect considerations](images/gerd-treatment-comparison.jpg)

## Key Clinical Pearls

Not all upper GI symptoms should be equated with GERD; H. pylori testing should precede PPI initiation in patients with dyspepsia. Weight loss is the most effective lifestyle modification for GERD and should be recommended to all overweight patients with reflux symptoms. PPI de-prescribing should be attempted after 4 to 8 weeks in most patients, and long-term use should require a documented indication. Rebound acid hypersecretion is self-limited, lasting 1 to 2 weeks, and should not be mistaken for recurrent disease requiring PPI reinitiation.

## References

1. Katz PO, et al. ACG Clinical Guideline: Guidelines for the Diagnosis and Management of GERD. *Am J Gastroenterol*. 2022;117(1):27-56.
2. Moayyedi PM, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. *Am J Gastroenterol*. 2017;112(7):988-1013.
3. Freedberg DE, et al. The risks and benefits of long-term use of proton pump inhibitors. *BMJ*. 2017;356:j2.
4. Dunbar KB, et al. AGA Clinical Practice Update on Screening and Surveillance of Barrett's Esophagus. *Gastroenterology*. 2023;164(1):26-32.